Hutchmed (china) Share Discussion Threads

[dbadvn] 06/8/2019 15:05

Yes, whichever way you look at it and from whomsoevers point of view (even Morgan’s)it was a very negative move.

What we used to call in the oil industry a real cluster...k.!!

[nerdofsteel] 06/8/2019 14:57

Also, the postponed HK listing pushes out any potential de-listing in London, a market that has ever understood Biotech and Biopharma apart the big players. I did think de-listing in London would only be a matter of time after a HK listing, and that may still happen in the future. It seems ironic to me that that way the Secondary listing was handled help to destroy some of the very Shareholder value CKH/HHHL created.

[steeplejack] 06/8/2019 12:48

Well,given the recent "let's deconsolidate at all costs ",I'm not so sure.Hutchinson will still hold a very influential stake of slightly less than half the equity.Holding under fifty per cent sort of establishes HCM's status as an independent company.As for investors,yes they're a flighty bunch.The number of listed companies both sides of the water has near halved in the last ten years......but we wouldn't want HCM to go private would we?

[thornyone] 06/8/2019 10:01

I feel safer with HCM controlled by Hutchison Group rather than investors.

[steeplejack] 05/8/2019 18:12

Thanks DBADVN.Much as I thought,

Morgan’s might have got shot of the stock but we don’t know at what price.They took a loss having procured the placing at $24.Theres going to be some indigestion and the market as a whole is undergoing a correction but I’m pretty convinced this is an excellent long term buy.

[nerdofsteel] 05/8/2019 16:52

The syk inhibitor 523 is forecast to have China sales of $149m and global sales of $548m

It could be first-in-class, there are only 2 others in development, also in phase 2, Gilead 9876 (Entospletinib) and Shire/Takeda TAK-659

We really need to push this asset along quickly now because whoever launches first will not only get the advantages of sales growth they will also get the kudos of being the first clinical dev Team to address Syk.

[nerdofsteel] 05/8/2019 16:31

Thanks for posting DBADVN, all great intel and "Hutchison Group v upset at drop in share price", well more fool them I say, they engineered the downfall and should have known better.

"By target price of £57"... i assume in new money that is a 1 year target of £5.70?

"not sure what CHM share would be"

From 9% up to 18% tiered royalty ex-Chin & 30% flat rate
China royalty on all product revenues

Base royalty of 9%-13%. Additional 5% royalty subject to approval in the papillary renal cell carcinoma (PRCC) indication, for a total of 14%-18% tiered royalty. After total aggregate sales of savolitinib have reached $5bn, the royalty will step down over a two-year period, to an ongoing royalty rate of 10.5% to 14.5%.

[shaker44] 05/8/2019 15:38

Many thanks. Great summary

[nerdofsteel] 05/8/2019 11:22

An interesting article from today's SCMP on the current investment landscape on Biopharma investing in China & HK

[nerdofsteel] 04/8/2019 14:54

Nice to see Brad Loncar posting fairly regularly on $HCM

[nerdofsteel] 03/8/2019 15:54

Astrazeneca ;o-)

[its the oxman] 02/8/2019 16:31

Please do share, we could certainly do with some encouragement.

[dbadvn] 02/8/2019 15:54

Sjack, you are more correct than you can possibly believe. Following meeting with c Hogg I am now moving from selling to serious buying. More later when I get back home.

[steeplejack] 02/8/2019 13:41

Nothing's fundamentally changed here from the days when the stock was the equivalent of well over £5.Progress has been made on drug development but we are suffering the logistical consequences of a badly handled placing.Simply,there are too few buyers chasing too much stock.It'll pass.

[its the oxman] 02/8/2019 10:53

Just have to pray co. can up the newsflow and that updates going forward will be positive and start to underpin the upside from these low levels.

[steeplejack] 01/8/2019 19:31

I'd be interested to know how Morgan Stanley got to do the Nasdaq placing when originally it was Goldmans and Merrill Lynch who were sponsoring the proposed placing in Hong Kong.I presume Morgan's bid for the deal.There's another one percent odd of Hutchinson holding to sell before they can deconsolidate HCM as a subsidiary.What might be their plans in this respect.Would they consider a private placement....that's what I think they should consider doing.The Morgan Stanley placing has done enough damage.

[its the oxman] 01/8/2019 15:30

Suspect buyers will soon decide this is too oversold and we will spike up, just a question of when. That's my belief anyway.

[steeplejack] 31/7/2019 20:48

I suspect,doing a back of the envelope calculation,that Morgan S.must have placed the greater part of the Hutchinson stock.They might carry some in the hope of recouping some losses as the stock recovers.I think the worst is past.

[nerdofsteel] 31/7/2019 07:07

Interesting that Seroquel wasn't mentioned yesterday. I assume Analaysts have taken the view that it only produced $1.7m net income in FY2018 so it's no longer as important as it used to be. And judging by the questions you can see most Analysts are new to Chi-Med and have probably never heard of Seroquel! In Law if the agreement was assigned to Luye they no basis to terminate and are on a very sticky wicket.